Effects of Olmesartan Medoxomil Angiotensin Type 1 (AT1) Receptor Blocker 1 in Selected Patients with Nonalcoholic Steatohepatitis (NASH): Pilot Study

Effects of Olmesartan Medoxomil Angiotensin Type 1 (AT1) Receptor Blocker 1 in Selected Patients with Nonalcoholic Steatohepatitis (NASH): Pilot Study - Effects of Olmesartan Medoxomil Angiotensin Type 1 (AT1) Receptor Blocker 1 in Selected Patients with Nonalcoholic Steatohepatitis (NASH): Pilot Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005409

Enrollment

Registered

2011-05-01

Start date

2008-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with nonalcoholic steatohepatitis (NASH)

Interventions

Olmesartan Medoxomil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Proven NASH with a diagnosis based on histology. (2) Alcoholic etiology of cirrhosis had to have abstained from alcohol for more 3 months before the start of the study. (3) Child-Pugh score is less than 10. (4) Absent or small esophageal varices.

Exclusion criteria

Exclusion criteria: (1)Mean arterial pressure is less than 60 mmHg. (2)ARB intolerance. (3)Current treatment with ARB, angiotensin-converting enzyme inhibitors, or beta blockers. (4)Hypertrophic cardiomyopathy or renal arterial stenosis. (5)Serum creatinine is more than 1.6 mg/dL. (6)Hyperkalemia defined as plasma potassium more than 5.5 meq/L. (7)Hepatocellular carcinoma. (8)Portal venous tumor thrombosis.

Design outcomes

Primary

Measure	Time frame
Changes of liver fibrosis marker	—

Countries

Japan

Contacts

Public ContactHisashi Hidaka

Kitasato University East Hospital Department of Gastroenterology, Internal Medicine

hisashi7@kitasato-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026